Gas-filled microbubbles as intravascular R(2)* contrast agent for liver MRI by Yu, A et al.
Title Gas-filled microbubbles as intravascular R(2)* contrast agent forliver MRI
Author(s) Chow, AMK; Cheung, JSC; Yu, A; Guo, H; Wu, EX
Citation
The 17th Scientific Meeting & Exhibition of the International
Society of Magnetic Resonance in Medicine (ISMRM), Honolulu,
HI., 18-24 April 2009. In Proceedings of ISMRM 17th Scientific
Meeting & Exhibition, 2009, p. 723
Issued Date 2009
URL http://hdl.handle.net/10722/62094
Rights Creative Commons: Attribution 3.0 Hong Kong License
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INTRODUCTION 
Gas-filled microbubbles possess the potential to become a unique MR contrast agent because of their magnetic susceptibility effect, high biocompatibility and unique 
cavitation and sonoporation properties. However, in vivo demonstration of microbubble susceptibility effect is limited so far. In this study, we aim to further 
demonstrate and characterize the in vivo MR susceptibility effect induced by using both custom-made albumin-coated microbubbles (AMB) and commercially available 
lipid-based clinical ultrasound microbubble contrast agent (SonoVue®) in rat livers at 7 Tesla using dynamic susceptibility weighted MRI. 
METHODS 
Microbubbles Preparation: Air-filled AMBs were produced by sonication as previously described1. SonoVue® microbubbles (Bracco) are commercially available, 
which consist of sulphur hexafluoride gas stabilized in aqueous dispersion by phospholipid monolayer. Animal Procedures: Normal SD rats (~250-350 g) (N = 5) were 
used. Femoral vein catheterization was performed with a 1-m long tube connected to a 27-gauge needle under anesthetization using IP injection of ketamine (100 
mg/kg) and xylazine (10 mg/kg). The dead space in the catheter was about 0.2 mL. During MRI, animals were anesthetized with isoflurane/air using 1.0-1.5% via a 
nose cone. Microbubbles Administration: Microbubbles were first warmed slowly to room temperature and mixed to achieve uniform suspension. For each imaging 
session, 0.2 mL of microbubble suspension (~4% volume fraction for AMB and ~3.5% volume fraction for SonoVue®) was slowly injected at a rate of 1.2 mL/min to 
avoid possible microbubble destruction due to high pressure and shear stress. MRI: All MRI experiments were performed on a 7 T Bruker MRI scanner using a 60-mm 
quadrature RF coil. Anatomical images were acquired with 2D FLASH sequence with resolution = 0.20 × 0.20 × 2.0 mm3. Dynamic susceptibility weighted liver MRI 
was performed with respiratory-gated single-shot GE-EPI sequence using TR ≈ 1000 ms, TE = 10 ms, FA = 90º, FOV = 50 mm × 50 mm, slice thickness = 2 mm, 
acquisition matrix = 64 × 64, BW = 221 kHz and NEX = 1.  To allow sufficient clearance of the microbubbles before the next injection, a minimum lapse of 10 min was 
used. The susceptibility effect of microbubbles was compared with that of a well-established intravascular contrast agent, monocrystalline iron oxide nanoparticles 
(MION; MGH), by single dose of 0.6 mg Fe/kg injection using identical injection protocol and imaging sequence. Image Analysis: GE-EPI images were first co-
registered using AIR5.2.52. ΔR2* maps were computed on a pixel-by-pixel basis as ΔR2* = ln (Spre/Savg-post)/TE, where Spre is the average intensity in 100 preinjection 
images and Savg-post is the average intensity in 40 postinjection images with maximum susceptibility contrast for microbubbles (or 100 postinjection images at steady-
state contrast for MION). To quantify the ΔR2* values, ROIs were manually drawn in homogeneous liver region (LV) and the region covering inferior vena cava (IVC) 
based on the high resolution FLASH images. Assuming that ΔR2* is proportional to microbubble concentration C(t) at time t, C(t) can be estimated as C(t) = k ln 
{Spre/S(t)}/TE + CB, where S(t) is the image intensity at time t, k a proportionality constant, and CB a constant residue to account for any postinjection baseline3. Given 
the relatively long injection time and the limited lifetime of microbubbles in vivo, C(t) were approximately modeled with a gamma-variate function by curve fitting4. 
Full width at half maximum (FWHM) and time-to-peak were then measured from the fitted C(t) time courses. Ultrasound Demonstration: Ultrasound imaging (Sonix 
RP, Ultrasonix) was preformed in rat livers (N = 2) using SonoVue® to demonstrate microbubble induced contrast change for comparison. 
RESULTS AND DISCUSSIONS 
Figure 1(a) shows one of the preinjection GE-EPI T2*-weighted images, while (b) shows the postinjection GE-
EPI T2*-weighted image with the maximum susceptibility contrast for AMB injection. Figure 2 depicts the 
typical T2*-weighted signal time courses during microbubbles injection with ROIs indicated in Figure 1(a). Two 
ROIs were selected from LV and IVC. The signal time course during SonoVue® injection captured by 
ultrasound imaging was overlaid in red for comparison. Note that the ultrasound signal was enhanced by 
microbubbles. Similar signal recovering patterns were observed, showing comparable lifetime of SonoVue® in 
vivo. The computed ∆R2* maps for AMB, SonoVue® and MION in the same animal were shown in Figure 3 and 
were found to be similar. However, the blood vessels in MION ∆R2* map were not as bright as those in 
microbubble ∆R2* maps, likely caused by the dominant T1 shortening effect of MION at the low dosage used. 
Table 1 shows the in vivo measurements of the ∆R2*, FWHM and time-to-peak of AMB and SonoVue® as well 
as the ∆R2* and time-to-peak of MION in liver among all rats studied. The similar ∆R2* indicates that the in vivo 
susceptibility effects of AMB and SonoVue® at the dosage used are comparable to 
that of 0.6 mg Fe/kg MION in liver tissue at 7 T. However, time-to-peak was found 
to be shorter for MION. This is largely expected as microbubbles, with size 
comparable to that of red blood cells, flow slower than blood plasma while nano-
sized MIONs flow together with plasma. In few of the rats studied (2 out of 5), the 
T2*-weighted signals after microbubble injection did not return to the preinjection 
baseline, this may be caused by microbubble trapping in local tissue vasculature. 
Possible uptake of intact microbubbles by Kupffer cells in liver may also contribute 
to such observation.  
CONCLUSIONS  
Substantial susceptibility induced changes were observed and characterized using 
gas-filled microbubbles for MRI at 7 T in rat livers, using custom-made albumin-
coated microbubbles and a commercially available clinical ultrasound microbubble 
contrast agent. With the increasing availability of high-field MRI systems in both 
clinical and research setting, gas-filled microbubbles offer the promise as a viable 
intravascular contrast agent since their MR susceptibility effect increases5 with Bo2. 
With the unique cavitation and sonoporation characteristics, microbubble MRI has 
the potential for MRI guidance of microbubble-based drug delivery and therapies. 
Microbubble fabrication technology is also advancing. For example, substantially 
increased in vivo lifetime has been demonstrated recently using surfactant molecules 
with multiphase mixing technique6. Lastly, molecular targeting capability can also be 
achieved by microbubble surface modification7. 
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Figure 1 GE-EPI T2*-weighted image for AMB (0.2 mL of 
~4% volume fraction) (a) preinjection image and (b) 
postinjection with the maximum susceptibility contrast. 
     
Figure 2 T2*-weighted signal time courses in different liver regions during (a) AMB and 
(b) SonoVue® injection in the same rat. Two ROIs for time course measurement, a 
homogenous liver region (LV) and the region covering inferior vena cava (IVC), are shown 
in Figure 1(a). Gamma-variate fitted data are shown in sold lines. Ultrasound measurement 
(red line) was overlaid in (b) for comparison. 
   
Figure 3 ∆R2* maps for (a) AMB, (b) SonoVue® and (c) 0.6 mg Fe/kg MION. 
Table 1 Measurements of ∆R2*, FWHM and time-to-peak of the concentration time courses 
for AMB, SonoVue® and MION in rat liver (mean ± standard deviation, N = 5). 
 ΔR2* (s-1) FWHM (s) Time-to-peak (s) 
AMB 40.89 ± 22.08 119 ± 68 60 ± 24 
SonoVue® 45.78 ± 34.22 95 ± 41 58 ± 28 
MION 55.84 ± 21.75 N.A. 39 ± 14 
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